LeMaitre Vascular (NASDAQ:LMAT) Given New $93.00 Price Target at Barrington Research

LeMaitre Vascular (NASDAQ:LMAT) had its target price boosted by research analysts at Barrington Research from $92.00 to $93.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price target would indicate a potential downside of 7.00% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. JMP Securities upped their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Cantor Fitzgerald started coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.83.

LeMaitre Vascular Trading Up 13.1 %

LMAT stock traded up $11.61 during midday trading on Friday, hitting $100.00. The stock had a trading volume of 75,711 shares, compared to its average volume of 122,084. The firm has a market cap of $2.25 billion, a P/E ratio of 59.89, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88. The business has a fifty day moving average price of $89.53 and a two-hundred day moving average price of $82.77. LeMaitre Vascular has a 1-year low of $45.96 and a 1-year high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.33 earnings per share. On average, equities analysts anticipate that LeMaitre Vascular will post 1.86 EPS for the current year.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of the business. Conestoga Capital Advisors LLC grew its stake in LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after purchasing an additional 4,964 shares in the last quarter. Copeland Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after buying an additional 11,318 shares during the last quarter. Congress Asset Management Co. increased its holdings in shares of LeMaitre Vascular by 2.6% in the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after purchasing an additional 18,295 shares during the period. Finally, Driehaus Capital Management LLC raised its position in LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after buying an additional 90,573 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.